ClinicalTrials.gg
RecruitingNCT04586959MAN-UUpdated Nov 18, 2026

Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer

An interventional study of Surgery with UM and Surgery without UM in ENDOMETRIAL CANCER, sponsored by Anthony Costales, MD. Recruiting at 5 sites in United States. Open to female participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Anthony Costales, MD · Not applicable, Interventional, and Treatment

How we know · 2 judgments

From the registry’s dates

  • Started May 2021; still recruiting 5 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
278
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 715 studies in Endometrial Neoplasms with a site in United States — 195 open to participants now, 284 under way, 22 of them phase 3. Endometrial Neoplasms · United States.

Planned enrollment
100th of 591
278 · median 60
Started
2021
with 56 others
No phase
116 of 715
29 open now
Primary completion
2027-07
later than 125 of 283 live
Registered
422nd of 715
by date

Among the 715 studies in Endometrial Neoplasms with a site in United States, this one is the 100th largest by planned enrollment of the 591 interventional ones that give a count, is one of 57 that started in 2021, is one of 116 with no phase, reaches primary completion later than 125 of the 283 other live ones, and was the 422nd registered.

Endometrial Neoplasms

1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

195 of the 715 studies in Endometrial Neoplasms with a site in United States are open now. Recruiting first, the newest first:

190 more — sign in →

All 195 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 90 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 715 studies in Endometrial Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a prospective, multi-center, randomized non-inferiority phase III study to evaluate if patients undergoing a minimally invasive surgery for early stage uterine cancer have cancer cells in the fluid that is obtained at the time of their surgery when a uterine manipulator is placed versus patients who do not have a uterine manipulator placed.

Read the detailed description

In most cases, patients who have early stage endometrial cancer undergo a surgery to remove the uterus, cervix, tubes, ovaries, and occasionally lymph nodes. This is usually done through a minimally invasive (not a large incision) surgery. To accomplish this, the uterus needs to be manipulated (moved around) to help the surgeon complete your surgery. This is usually done with a device called a uterine manipulator and the majority of surgeons use this device in any patient undergoing a minimally invasive hysterectomy (removal of the uterus and cervix).

Even though the majority of surgeons use a manipulator, there are some surgeons who believe there is a possibility that cancer cells inside the uterus can be spilled into the abdomen through the fallopian tubes. This may cause a higher risk of spreading the cancer and or of the cancer coming back.

Currently, there are very limited research studies directly looking at whether the uterine manipulator may cause these cells to appear in the abdomen.

The purpose of this study is to see if patients undergoing a minimally invasive surgery for early stage uterine cancer have cancer cells in the fluid that is obtained at the time of their surgery when a uterine manipulator is placed versus patients who do not have a uterine manipulator placed.

A computer program will randomly assign the subjects to one of two groups. One group will have minimally invasive surgery with the use of a uterine manipulator and the other group will have minimally invasive surgery without the use of a uterine manipulator.

Researchers will use the information from this study to decide how best to take care of patients undergoing minimally invasive surgery for uterine cancer.

03

Conditions studied

  • ENDOMETRIAL CANCER

Keywords

  • endometrial
  • cancer
  • uterine
  • manipulator
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A subject will be considered eligible for inclusion in this study if all the following criteria are met:

  1. Patient must be greater than or equal to 18 years old.
  2. Suspected clinically early stage endometrial cancer of any histology (endometrioid, mixed, serous, clear-cell, carcinosarcomas, mucinous)
  3. Pre-operative imaging not suggestive of extra-uterine disease, if obtained pre-operatively.
  4. CA 125 testing is optional but, if obtained, must be within lab normal values. 5. performance status 0-2 (see appendix 1).

6. Signed and ability to comply with follow-up. 7. Per the opinion of the treating investigator, the patient must be a suitable candidate for the MIS surgical procedure.

Exclusion criteria

Exclusion Criteria:

A subject must not have any of the following criteria:

  1. Planned laparotomic hysterectomy
  2. On progesterone therapy to treat their endometrial cancer
  3. Any prior pelvic irradiation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
278 participants (estimated)

Study arms

  • Experimental
    Surgery With UM (Arm MAN UA)

    Subjects that undergo a MIS approach with a uterine manipulator (experimental arm)

    Device: Surgery with UM

  • Active comparator
    Surgery Without UM (Arm Control)

    Subjects that undergo a MIS approach without a uterine manipulator (control arm)

    Device: Surgery without UM

Interventions

  • DeviceSurgery with UM

    The experimental group will have MIS with the placement of a uterine manipulator

  • DeviceSurgery without UM

    The control group will have MIS without the placement of a uterine manipulator

06

What researchers measure

Primary outcomes

  1. Positive peritoneal cytology (PC)

    Positive PC is defined as the presence of malignant cells in the peritoneal cytology specimen.

    Time frame: Immediately after uterine manipulator placement in the manipulator group or prior to the initiation of the hysterectomy procedure in the non-manipulator group

Secondary outcomes

  1. Post-operative positive PC

    Positive PC is defined as the presence of malignant cells in the peritoneal cytology specimen.

    Time frame: Immediately after closure of the vaginal cuff

  2. Lymphovascular space invasion (LVSI)

    LVSI is defined as the presence of tumor cells within a definite endothelial-lined space (lymphatics or blood vessels) at the advancing edge of the tumor as it invades the myometrium, within an endometrial polyp, or within the endometrial stroma.

    Time frame: During surgery

  3. Percentage of myometrial invasion (MI)

    Defined as the % of invasion into the myometrium from the endomyometrial junction

    Time frame: During surgery

  4. Extent of lymph node metastases

    Defined as presence of isolated tumor cells (ITC - \<0.2 mm), or micrometastasis (mm - 0.2 - 2 mm), or macrometastasis (MM - \> 2 mm), whichever is greater.

    Time frame: During surgery

  5. Operative time

    Defined as time from start of operation to closure of skin in minutes as documented in the electronic medical record

    Time frame: 1 day

  6. Surgical morbidity

    Surgical morbidity (CTCAE v5.0) grade 3 and higher, or any grade of the following adverse events: colonic fistula, colonic perforation, enterovesical fistula, gastrointestinal fistula, ileus, intra-abdominal hemorrhage, rectal fistula, rectal perforation, small intestinal perforation, abdominal infection, pelvic infection, vaginal infection, intra-operative arterial injury, venous injury, intra-operative gastrointestinal injury, intra-operative hemorrhage, intra-operative neurological injury, intra-operative urinary injury, and post-operative hemorrhage.

    Time frame: Intra-operative and up to 30 days post-surgery

07

Study locations

4 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for Jul 2027, 74 months after the start.

Of 194 non-industry interventional studies with no phase under Endometrial Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 76. This study's planned 74 months is above that.

Counting every sponsor, half of 200 studies reached it within 43 months; a quarter within 19 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2020
First posted
Oct 14, 2020
StartActual
May 21, 2021
Primary completionEst.
Jul 2027
CompletionEst.
Oct 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04586959
Lead sponsor
Anthony Costales, MD
Responsible party
Anthony Costales, MD (Assistant Professor Obstetrics & Gynecology, Baylor College of Medicine) — Sponsor-investigator
First posted
Oct 14, 2020
Start date
May 21, 2021
Primary completion
Jul 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Anthony Costales, MD
Contact
costales@bcm.edu
713-798-3495
Roberto Vargas, MD
Contact
vargasr@ccf.org
216-444-3414
Anthony Costales, MD
principal investigator · Baylor College of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion